This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matthews, D. C. Articles by Bernstein, I. D. Search for Related Content PubMed PubMed Citation Articles by Matthews, D. C. Articles by Bernstein, I. D.

Selective Radiation of Hematolymphoid Tissue Delivered by Anti-CD45 Antibody¹

Division of Clinical Research [D. C. M., C. C. B., C. N., F. R. A., P. J. M., I. D. B.], Fred Hutchinson Cancer Research Center, Seattle, Washington 98104; Departments of Pediatrics [D. C. M., I. D. B.] and Medicine [C. C. B., F. R. A., P. J. M.], University of Washington, Seattle, Washington 98195; and Battelle Pacific Northwest Laboratories, Richland, Washington 99352 [D. R. F., T. E. H.]

The ability to deliver radiation selectively to lymphohematopoietic tissues may have utility in conditions treated by myeloablative regimens followed by bone marrow transplantation. Since the CD45 antigen is the most broadly expressed of hematopoietic antigens, we examined the biodistribution of radiolabeled anti-CD45 monoclonal antibodies in normal mice. Trace ¹²⁵I or ¹³¹I-labeled monoclonal antibodies 30G12 (rat IgG2a), 30F11 (rat IgG2b), and F(ab')₂ fragments of 30F11 were injected i.v. at doses of 5 to 1000 µg. For both intact antibodies, a higher percentage of injected dose/g (% ID/g tissue) in blood was achieved with higher antibody doses. However, as the dose of antibody was increased, the % ID/g in the target organs of spleen, marrow, and lymph nodes decreased. At doses between 5 and 10-µg, % ID/g in these tissues exceeded that in lung, the normal organ with the highest concentration of radiolabel. In contrast, thymus was the only hematopoietic organ in which the % ID/g increased with increasing antibody dose, although at high dose the % ID/g was still far below that achieved in the other hematopoietic organs. Antibody 30F11 F(ab')₂ fragments were cleared more quickly than intact antibody from blood and from both target and nontarget organs, although the relationship between increasing antibody dose and decreasing % ID/g in spleen, marrow, and lymph nodes was observed. The time-activity curves for each dose of antibody were used to calculate estimates of radiation absorbed dose to each organ. At the 10-µg dose of 30G12, the spleen was estimated to receive a radiation dose that was 13 times more than lung, the lymph nodes 3 to 4 times more, and the bone marrow 3 times more than lung. For each antibody fragment dose, the radiation absorbed dose per MBq ¹³¹I administered was lower because the residence times of the fragments were shorter than those of the intact antibody. Thus these estimates suggested that the best "therapeutic ratio" of radiation delivered to target organ as compared to lung was achieved with lower doses of intact antibody. We have demonstrated that radiolabeled anti-CD45 monoclonal antibodies can deliver radiation to lymphohematopoietic tissues with relative selectivity and that the relative uptake and retention in different hematolymphoid tissues change with increasing antibody dose.

¹ This work was supported by the Leukemia Society of America (D. C. Matthews, Fellow) and aided by Grant IN-26-32 from the American Cancer Society and by Grant CA 26836 from the National Cancer Institute.

² To whom requests for reprints should be addressed.

Received 7/30/91. Accepted 12/13/91.

This article has been cited by other articles:

				Y. Lin, J. M. Pagel, D. Axworthy, A. Pantelias, N. Hedin, and O. W. Press A Genetically Engineered Anti-CD45 Single-Chain Antibody-Streptavidin Fusion Protein for Pretargeted Radioimmunotherapy of Hematologic Malignancies. Cancer Res., April 1, 2006; 66(7): 3884 - 3892. [Abstract] [Full Text] [PDF]

				J. M. Pagel, F. R. Appelbaum, J. F. Eary, J. Rajendran, D. R. Fisher, T. Gooley, K. Ruffner, E. Nemecek, E. Sickle, L. Durack, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission Blood, March 1, 2006; 107(5): 2184 - 2191. [Abstract] [Full Text] [PDF]

				E. R. Nemecek, D. K. Hamlin, D. R. Fisher, K. A. Krohn, J. M. Pagel, F. R. Appelbaum, O. W. Press, and D. C. Matthews Biodistribution of Yttrium-90-Labeled Anti-CD45 Antibody in a Nonhuman Primate Model Clin. Cancer Res., January 15, 2005; 11(2): 787 - 794. [Abstract] [Full Text] [PDF]

				W. A. Bethge, D. S. Wilbur, R. Storb, D. K. Hamlin, E. B. Santos, M. W. Brechbiel, D. R. Fisher, and B. M. Sandmaier Selective T-cell ablation with bismuth-213-labeled anti-TCR{alpha}{beta} as nonmyeloablative conditioning for allogeneic canine marrow transplantation Blood, June 15, 2003; 101(12): 5068 - 5075. [Abstract] [Full Text] [PDF]

				M. K. BRENNER, G. G. WULF, D. R. RILL, K.-L. LUO, M. A. GOODELL, Z. MEI, I. KUEHNLE, M. P. BROWN, M. PULE, H. E. HESLOP, et al. Complement-Fixing CD45 Monoclonal Antibodies to Facilitate Stem Cell Transplantation in Mouse and Man Ann. N.Y. Acad. Sci., May 1, 2003; 996(1): 80 - 88. [Abstract] [Full Text] [PDF]

				G. G. Wulf, K.-L. Luo, M. A. Goodell, and M. K. Brenner Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation Blood, March 15, 2003; 101(6): 2434 - 2439. [Abstract] [Full Text] [PDF]

				B. M. Sandmaier, W. A. Bethge, D. S. Wilbur, D. K. Hamlin, E. B. Santos, M. W. Brechbiel, D. R. Fisher, and R. Storb Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts Blood, June 17, 2002; 100(1): 318 - 326. [Abstract] [Full Text] [PDF]

				A. Countouriotis, T. B. Moore, and K. M. Sakamoto Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies Stem Cells, May 1, 2002; 20(3): 215 - 229. [Abstract] [Full Text] [PDF]

				K. L. Ruffner, P. J. Martin, S. Hussell, C. Nourigat, D. R. Fisher, I. D. Bernstein, and D. C. Matthews Immunosuppressive Effects of 131I-Anti-CD45 Antibody in Unsensitized and Donor Antigen-presensitized H2-matched, Minor Antigen-mismatched Murine Transplant Models Cancer Res., July 1, 2001; 61(13): 5126 - 5131. [Abstract] [Full Text] [PDF]

				F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick Acute Myeloid Leukemia Hematology, January 1, 2001; 2001(1): 62 - 86. [Abstract] [Full Text] [PDF]

				D. C. Matthews, F. R. Appelbaum, J. F. Eary, D. R. Fisher, L. D. Durack, T. E. Hui, P. J. Martin, D. Mitchell, O. W. Press, R. Storb, et al. Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome Blood, August 15, 1999; 94(4): 1237 - 1247. [Abstract] [Full Text] [PDF]

				D. C. Matthews, P. J. Martin, C. Nourigat, F. R. Appelbaum, D. R. Fisher, and I. D. Bernstein Marrow Ablative and Immunosuppressive Effects of 131I-Anti-CD45 Antibody in Congenic and H2-Mismatched Murine Transplant Models Blood, January 15, 1999; 93(2): 737 - 745. [Abstract] [Full Text] [PDF]